{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["26(1)"],"submitter":["Bouthelier A"],"pubmed_abstract":["Inhibition of the heterodimeric amino acid carrier SLC7A5/SLC3A2 (LAT1/CD98) has been widely studied in tumor biology but its role in physiological conditions remains largely unknown. Here we show that the SLC7A5/SLC3A2 heterodimer is constitutively present at different stages of erythroid differentiation but absent in mature erythrocytes. Administration of erythropoietin (EPO) further induces SLC7A5/SLC3A2 expression in circulating reticulocytes, as it also occurs in anemic conditions. Although <i>Slc7a5</i> gene inactivation in the erythrocyte lineage does not compromise the total number of circulating red blood cells (RBCs), their size and hemoglobin content are significantly reduced accompanied by a diminished erythroblast mTORC1 activity. Furthermore circulating <i>Slc7a5</i>-deficien"],"journal":["iScience"],"pagination":["105739"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9792907"],"repository":["biostudies-literature"],"pubmed_title":["Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation."],"pmcid":["PMC9792907"],"pubmed_authors":["Cibrian D","Marcos-Jimenez A","Monroy F","Pacheco AM","Quiroga B","Bouthelier A","Castillo-Gonzalez R","Sanchez-Madrid F","Aragones J","Morado M","Urrutia AA","Guajardo-Grence A","Calero M","Munoz-Calleja C","Fernandez-Arroyo L","Mesa-Ciller C","Martin-Cofreces NB","Herraez-Aguilar D"],"additional_accession":[]},"is_claimable":false,"name":"Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation.","description":"Inhibition of the heterodimeric amino acid carrier SLC7A5/SLC3A2 (LAT1/CD98) has been widely studied in tumor biology but its role in physiological conditions remains largely unknown. Here we show that the SLC7A5/SLC3A2 heterodimer is constitutively present at different stages of erythroid differentiation but absent in mature erythrocytes. Administration of erythropoietin (EPO) further induces SLC7A5/SLC3A2 expression in circulating reticulocytes, as it also occurs in anemic conditions. Although <i>Slc7a5</i> gene inactivation in the erythrocyte lineage does not compromise the total number of circulating red blood cells (RBCs), their size and hemoglobin content are significantly reduced accompanied by a diminished erythroblast mTORC1 activity. Furthermore circulating <i>Slc7a5</i>-deficien","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T14:10:49.327Z","creation":"2025-04-04T14:10:49.327Z"},"accession":"S-EPMC9792907","cross_references":{"pubmed":["36582828"],"doi":["10.1016/j.isci.2022.105739"]}}